hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 21:29:07 - browse：3

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Bernie Sanders gets little from pharma CEOs on drug prices

WSS

Having children helps parents live longer, especially after age 80

Abbott's new heart device gets FDA advisory panel nod

Too many hospitalized Covid

NIH confirmation hearing shows politicization of research

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Doctors on social media are being harassed and cyberbullied

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Long Covid research funding gets a major boost from NIH

Bright Health sells Medicare Advantage business to Molina

Juul documents reveal insider tactics on political lobbying

United colonoscopy coverage change 'may cost lives,' doctors say

Here’s what’s in the FDA plan to include pregnant women in clinical trials

State Dept. review finds Biden bears some blame for Afghanistan failures

Bernie Sanders gets little from pharma CEOs on drug prices

Heart attack and stroke risk calculators need revising

The explosion of genetic testing requires a new approach

entertainment

Report cites 'urgent' need to recruit more diverse clinical trial participants

Having children helps parents live longer, especially after age 80

HHS leader on health, climate change and biopharma emissions

Study gives hint on South Asians’ higher risk of cardiovascular disease

Long Covid research funding gets a major boost from NIH

UnitedHealth’s board chair also owns a personal investment firm

focus

hotspot

leisure time

Wikipedia